

A guide to Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Histopathology Reporting



Includes the  International Collaboration on Cancer reporting dataset denoted by *

Clinical details

S1.02 Clinical information provided on request form (complete as narrative or use the structured format below)	Text
*Genetic status	BRCA1 BRCA2 Lynch syndrome Other (specify) Not known
*Prior chemotherapy	Prior chemo. admin. No chemo. admin. Not specified
Previous gynaecological procedure/treatment	Text
Operative procedure	See p4
Operative findings	Text
New primary tumour or recurrence	New primary Local recurrence Distant met.
If regional (local) recurrence or distant metastasis describe	Text
S1.03 Pathology accession number	Text
S1.04 Principal clinician	Text
G1.01 Other clinical info. received	Text

Macroscopic findings

S2.02 Specimen labelled as	Text
S2.03 *Specimen type (Note: For each specimen received, record S2.04-6 and consider recording G2.01- 6 as applicable.)	See p4
RIGHT OVARY	
S2.04 *Specimen integrity	Ov. capsule intact Ov. capsule ruptured Tumour on surface Fragmented spec. Other (specify)
G2.01 Specimen weight (Note: This will primarily be the (ovary/adnexal mass weight))	___ g
G2.02 Dimensions	___x___x___mm
Description	Text
G2.03 *Tumour dimensions **	___x___x___mm
G2.04 Tumour description	Text
LEFT OVARY	
S2.04 *Specimen integrity	Ov. capsule intact Ov. capsule ruptured Tumour on surface Fragmented spec. Other (specify)
G2.01 Specimen weight (Note: This will primarily be the (ovary/adnexal mass weight))	___ g
G2.02 Dimensions	___x___x___mm
Description	Text
G2.03 *Tumour dimensions **	___x___x___mm
G2.04 Tumour description	Text

**Note: specify dimensions for each tumour.

Macroscopic findings

RIGHT FALLOPIAN TUBE	
S2.04 *Specimen integrity	Serosa intact Serosa ruptured T. on serosal surface Fragmented spec. Other (specify)
G2.02 Dimensions (Note: 2 dimensions (length x diameter) should be recorded as a minimum, if abnormal, a third dimension should be recorded.)	___x___x___mm
Fimbriae	Not identified Present
Description	Text
G2.03 *Tumour dimensions **	___x___x___mm
G2.04 Tumour description	Text
LEFT FALLOPIAN TUBE	
S2.04 *Specimen integrity	Serosa intact Serosa ruptured T. on serosal surface Fragmented spec. Other (specify)
G2.02 Dimensions (Note: 2 dimensions (length x diameter) should be recorded as a minimum, if abnormal, a third dimension should be recorded.)	___x___x___mm
Fimbriae	Not identified Present
Description	Text
G2.03 *Tumour dimensions**	___x___x___mm
G2.04 Tumour description	Text
UTERUS	
G2.01 Specimen weight (This will primarily be the (ovary/adnexal mass weight) A comment should be added to state what is included.)	___ g
G2.02 Dimensions (Note: superior to inferior x distance between cornu x anterior to posterior)	___x___x___mm
Description	Text
G2.03 *Tumour dimensions**	___x___x___mm
G2.04 Tumour description	Text
G2.02 OTHER SPECIMEN(S)	Text
S2.05 *MACRO. DESCRIPTION OF OMENTUM	
Omentum dimensions	___x___x___mm
Omental involvement	Not involved Involved
If involved record maximum dimension of largest deposit	___mm
G2.05 Number of metastatic deposits	___ OR Text
Size of metastatic deposit (Note: Repeat for each metastatic deposit.)	___mm

Macroscopic findings	
S2.06 *Macroscopic tumour site	See p4
G2.06 Lymph nodes	Text (describe)
S2.07 *Block identification key	Text
G2.07 Other macroscopic description	Text
Microscopic findings	
S3.01 *Histological tumour type	See p4
G3.01 *Pattern of invasion (Note: mucinous carcinoma only)	Expansile Infiltrative/destruct.
G3.02 *CARCINOSARCOMA SUBTYPES	
Epithelial	____% AND List subtypes
Sarcomatous	____% AND list type: Homologous Heterologous
	If Heterologous, record subtypes Text
S3.02 *TUMOUR GRADE (Note: If chemotherapy has been administered the grade of the pre-chemotherapy biopsy should be noted.) Complete as applicable for the tumour type.	
Serous carcinomas	Low grade High grade Cannot be graded
Endometrioid carcinomas	G1: Well different. G2: Mod. different. G3: Poorly different. GX: Can't be graded
Clear cell carcinomas	High grade
Undifferentiated carcinomas	High grade
Carcinosarcomas	High grade
G3.03 *Mucinous carcinomas	G1: Well different. G2: Mod. different. G3: Poorly different. GX: Can't be graded
G3.04 *Nodules of anaplastic carcinoma (Note: mucinous carcinomas only)	Not identified Present
S3.03 *BORDERLINE TUMOUR	Absent Present
	If present, record S3.04, S3.05, S3.06 and consider reporting G3.05
S3.04 *Histological tumour type	See p4
S3.05 *SPECIAL FEATURES	
Micropapillary architecture for serous borderline tumour (at least 5 mm in one dimension) (Note: Applicable to serous borderline tumours only)	Absent Present
Microinvasion (upper limit 5 mm)	Absent Present
G3.05 *Intraepithelial carcinoma for mucinous borderline tumour	Absent Present
S3.06 *IMPLANTS FOR SEROUS & SEROMUCINOUS BORDERLINE TUMOUR (Note: Applicable to serous and seromucinous borderline tumours only)	
Non-invasive implants	Not identified Present

Microscopic findings	
Non-invasive implants	Not identified Present
If present, record Type and	Epithelial Desmoplastic
Site(s)	Pelvic Abdominal
Invasive implants/Extra-ovarian low grade serous carcinoma	Not identified Present
If present, record Site(s)	Pelvic Abdominal
Indeterminate	Not identified Present
If present, record Site(s)	Pelvic Abdominal
G3.06 Size of the largest implant	____mm
S3.07 *Serous tubal intraepithelial carcinoma (STIC) (Note: only if fallopian tube(s) are submitted. Applicable to high grade serous carcinoma only)	Right FT Present – fimbrial Present -non-fimbrial Not identified Cannot be assessed AND Left FT Present – fimbrial Present -non-fimbrial Not identified Cannot be assessed
G3.07 Other significant tubal lesions	Text
G3.08 Histological features	Text
S3.08 *HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT	
Right ovary	Not involved Involved Cannot be assessed Not applicable
Left ovary	Not involved Involved Cannot be assessed Not applicable
Right ovarian capsule/surface	Not involved Involved Cannot be assessed Not applicable
Left ovarian capsule/surface	Not involved Involved Cannot be assessed Not applicable
Right fallopian tube	Not involved Involved Cannot be assessed Not applicable
Left fallopian tube	Not involved Involved Cannot be assessed Not applicable
Uterus (Note: for peritoneal involvement refer to Peritoneum (including uterine serosa) below)	Not involved Involved Cannot be assessed Not applicable
If involved record site(s)	Myometrium Endometrium Cervix
Peritoneum (including uterine serosa)	Not involved Involved Cannot be assessed Not applicable
If involved record site(s)	Pelvis (specify) Abdomen (specify)

Microscopic findings		
Omentum	Not involved Involved Cannot be assessed Not applicable	
If involved record level of involvement	Macroscopic Microscopic	
Other involved organs(s)/ sites(s)	Text	
G3.09 Site of tubal involvement	Indeterminate OR Fimbrial Non-fimbrial	
G3.10 Lymphovascular invasion	Present Not identified Cannot be assessed	
S3.09 *Lymph node status (Note: Required only if submitted.)	Not submitted Not involved Involved	
<p>If involved, record involvement as applicable. (Note: In some cases it may not be possible to record the actual number of nodes due to fragmentation of the specimen.)</p>		
REGIONAL - LEFT PELVIC		
Number of lymph nodes examined	_____	
Number of positive lymph nodes	_____	
REGIONAL - RIGHT PELVIC		
Number of lymph nodes examined	_____	
Number of positive lymph nodes	_____	
REGIONAL - PARA-AORTIC		
Number of lymph nodes examined	_____	
Number of positive lymph nodes	_____	
Maximum dimension of largest deposit in regional node	____mm	
NON - REGIONAL		
Site	Text	
Number of lymph nodes examined	_____	
Number of positive lymph nodes	_____	
(Note: Repeat "Site/Number of LN examined and Number of positive LN" segment as needed.)		
S3.10 *Peritoneal cytology	Negative Positive Indeterminate Not received	
G3.11 *Response to neoadjuvant therapy	Text OR No prior treatment Cannot be assessed	
G3.12 *COEXISTENT PATHOLOGY		
Endometriosis	Text (specify sites)	
Other	Text	

Microscopic findings		
G3.13 Optimal tumour block(s)	Text	
G3.14 Additional microscopic comment	Text	

Ancillary test findings		
G4.02 *Immunohistochemical markers	Text	
G4.03 *Molecular data	Text	
G4.01 Other ancillary findings	Text	

Synthesis and overview		
G5.01 *FIGO stage (2014 edition) (if applicable)	Text	
Site of Primary tumour	Ovary (OV) Fallopian tube (FT) Peritoneum (P) OR Undesignated: site of primary tumour cannot be assessed (X)	
Stage	See p4	
S5.01 Year and edition of staging system, if included	Text	
G5.02 Diagnostic summary	Text	
<p>Include:</p> <ul style="list-style-type: none"> a.Primary tumour site b.Histological type c.Tumour grade d.Ovarian surface involvement, if applicable e.Dimension of largest omental deposit, if applicable f.Involvement of other tissue/organs if present g.Peritoneal cytology status h.Lymph node status <p>In cases of borderline tumour document implants and type if present.</p>		
S5.02 Overarching comment (if applicable)	Text	
G5.03 Edition/version number of the RCPA protocol on which the report is based	Text	

NOTES

S1.02/S2.02 Operative procedure

- Left oophorectomy
- Right oophorectomy
- Left salpingo-oophorectomy
- Right salpingo-oophorectomy
- Left salpingectomy
- Right salpingectomy
- Peritoneal resection
- Omentectomy
- Total hysterectomy with bilateral salpingo-oophorectomy
- Other, (specify)

S2.03 Specimen type

- Not specified
- Right ovary
- Left ovary
- Right ovarian cystectomy
- Left ovarian cystectomy
- Right fallopian tube
- Left fallopian tube
- Uterus
- Cervix
- Omentum
- Peritoneal biopsies
- Peritoneal washings/ascitic fluid
- Lymph nodes (specify site/s)
- Other eg bowel, bladder, appendix (specify)

S2.06 Macroscopic tumour site

(Note: Required only if not previously reported in G2.02.)

- Indeterminate
- Left ovary
- Right ovary
- Left fallopian tube
 - Fimbrial
 - Non fimbrial
- Right fallopian tube
 - Fimbrial
 - Non fimbrial
- Peritoneum
- Other (specify)

S3.01/04 Histological Tumour Type

Ovary

Epithelial tumours

- Serous borderline tumour /Atypical proliferative serous tumour 8442/1
- Serous borderline tumour- micropapillary variant / Non-invasive low-grade serous carcinoma 8460/2
- Low-grade serous carcinoma 8460/3
- High-grade serous carcinoma 8461/3
- Mucinous borderline tumour / Atypical proliferative mucinous tumour8472/1
- Mucinous carcinoma 8480/3
- Endometrioid borderline tumour / Atypical proliferative endometrioid tumour8380/1
- Endometrioid carcinoma 8380/3
- Clear cell borderline tumour / Atypical proliferative clear cell tumour 8313/1
- Clear cell carcinoma 8310/3
- Borderline Brenner tumour / Atypical proliferative Brenner tumour 9000/1
- Malignant Brenner tumour 9000/3
- Seromucinous borderline tumour / Atypical proliferative seromucinous tumour 8474/1
- Seromucinous carcinoma 8474/3
- Undifferentiated carcinoma 8020/3

Mixed epithelial and mesenchymal tumours

- Carcinosarcoma 8980/3

Note: a code for mixed cell adenocarcinoma is not included in the above list but the code M8323/3 is recommended if this diagnosis is made.

G5.01 FIGO Stage

- I Tumour is confined to ovaries or fallopian tube(s)
- IA Tumour limited to 1 ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
- IB Tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumour on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
- IC Tumour limited to 1 or both ovaries or fallopian tubes, with any of the following:
 - IC1 Surgical spill
 - IC2 Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
 - IC3 Malignant cells in the ascites or peritoneal washings
- II Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer
 - IIA Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
 - IIB Extension to other pelvic intraperitoneal tissues
 - III Tumour involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
 - IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven):
 - IIIA1(i) Metastasis up to 10mm in greatest dimension
 - IIIA1(ii) Metastasis more than 10mm in greatest dimension
 - IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
 - IIIB Macroscopic peritoneal metastasis beyond the pelvis up to 2cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes
 - IIIC Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)
- IV Distant metastasis excluding peritoneal metastases
 - IVA Pleural effusion with positive cytology
 - IVB Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)

S3.01/04 Histological Tumour Type

Fallopian tube

Epithelial tumours

- Serous tubal intraepithelial carcinoma 8441/2
- Serous borderline tumour / Atypical proliferative serous tumour 8442/1
- Low-grade serous carcinoma 8460/3
- High-grade serous carcinoma 8461/3
- Endometrioid carcinoma 8380/3
- Undifferentiated carcinoma 8020/3
- Mucinous carcinoma 8480/3
- Transitional cell carcinoma 8120/3
- Clear cell carcinoma 8130/3

Mixed epithelial- mesenchymal tumours

- Carcinosarcoma

•

Peritoneum

Epithelial tumours of Müllerian type

- Serous borderline tumour / Atypical proliferative serous tumour 8442/1
- Low-grade serous carcinoma 8460/3
- High-grade serous carcinoma 8461/3
- Others